Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
Top Page
Kazia Therapeutics
(NASDAQ:KZIA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$7.50
▲(16.46% Upside)
Action:ReiteratedDate:02/28/26
The score is held down primarily by weak financial performance (minimal revenue, large ongoing losses, and persistent cash burn with negative equity). Technicals are a notable offset with strong momentum above major moving averages, but overbought signals add near-term risk; valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Diversified, brain‑penetrant oncology pipeline
A focused pipeline centered on a brain‑penetrant PI3K/mTOR inhibitor plus next‑gen programs gives durable strategic depth in high‑need CNS and aggressive solid tumors. Successful clinical progression would create lasting competitive differentiation and multiple value inflection points over the next 2–4 years.
Negative Factors
Persistent negative operating cash flow
Sustained negative operating and free cash flow indicates the business cannot self‑fund development and must rely on external capital. Over the medium term this raises funding risk and potential dilution, and magnifies execution risk if trial setbacks or slower enrollment increase cash burn beyond current projections.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified, brain‑penetrant oncology pipeline
A focused pipeline centered on a brain‑penetrant PI3K/mTOR inhibitor plus next‑gen programs gives durable strategic depth in high‑need CNS and aggressive solid tumors. Successful clinical progression would create lasting competitive differentiation and multiple value inflection points over the next 2–4 years.
Read all positive factors
Kazia Therapeutics (KZIA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$83.21M
Dividend YieldN/A
Average Volume (3M)209.48K
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue Growth-98.25%
EPS Growth63.05%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,335,992
10 Day Avg. Volume60,839
30 Day Avg. Volume209,481
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.26
Price to Sales (P/S)248.45
P/FCF Ratio-0.79
Enterprise Value/Market Cap-0.57
Enterprise Value/Revenue-2.40K
Enterprise Value/Gross Profit-2.40K
Enterprise Value/Ebitda2.60
Forecast
1Y Price Target
$19.00Price Target Upside195.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kazia Therapeutics Business Overview & Revenue Model
Company Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a poten...
How the Company Makes Money
null...
Kazia Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.71K | 42.00K | 2.31M | 555.00 | 10.00K | 15.18M |
| Gross Profit | 19.71K | 42.00K | 2.31M | 555.00 | 10.00K | 15.18M |
| EBITDA | -18.15M | -13.28M | -26.59M | -22.28M | -23.52M | -5.11M |
| Net Income | -22.27M | -20.70M | -26.78M | -20.47M | -25.01M | -8.42M |
Balance Sheet | ||||||
| Total Assets | 71.04M | 6.06M | 21.59M | 28.08M | 35.89M | 58.09M |
| Cash, Cash Equivalents and Short-Term Investments | 69.39M | 4.34M | 1.66M | 5.24M | 7.36M | 27.59M |
| Total Debt | 98.71K | 396.00K | 634.00K | 1.80M | 1.84M | 0.00 |
| Total Liabilities | 24.62M | 14.36M | 31.60M | 16.03M | 17.61M | 20.24M |
| Stockholders Equity | 46.42M | -8.30M | -10.02M | 12.05M | 18.27M | 37.85M |
Cash Flow | ||||||
| Free Cash Flow | -9.07M | -13.28M | -9.58M | -15.16M | -22.76M | -9.11M |
| Operating Cash Flow | -13.22M | -13.28M | -9.58M | -15.16M | -22.76M | -9.11M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -2.37M | 0.00 |
| Financing Cash Flow | 79.08M | 15.98M | 5.99M | 12.97M | 3.73M | 28.11M |
Kazia Therapeutics Technical Analysis
Neutral
6.44
Price Trends
7.08
Positive
7.92
Negative
7.90
Negative
Market Momentum
-0.05
Positive
48.78
Neutral
45.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KZIA, the sentiment is Neutral. The current price of 6.44 is below the 20-day moving average (MA) of 7.57, below the 50-day MA of 7.08, and below the 200-day MA of 7.90, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 45.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KZIA.
Kazia Therapeutics Risk Analysis
Kazia Therapeutics disclosed 37 risk factors in its most recent earnings report. Kazia Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Holders of the ADSs are not treated as holders of our ordinary shares. Q2, 2024
2.
We have a history of operating losses and we expect to continue to incur losses and may never be profitable. Q2, 2024
3.
If the Company fails to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if the Company discovers material weaknesses and other deficiencies in our internal control and accounting procedures, the price of the ADSs could decline significantly and raising capital could be more difficult. Q2, 2024
Kazia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $14.64M | -0.72 | -107.58% | ― | ― | 83.95% | |
49 Neutral | $83.21M | -0.65 | -116.86% | ― | -98.25% | 63.05% | |
| ― | $6.01M | -5.56 | ― | ― | ― | 65.45% | |
49 Neutral | $8.22M | -0.46 | -684.86% | ― | ― | 96.75% | |
44 Neutral | $23.51M | -3.35 | >-0.01% | ― | -12.99% | -13.67% |
* Healthcare Sector Average
KZIA
Kazia Therapeutics
7.34
3.87
111.53%
PHIO
Phio Pharmaceuticals
1.26
0.25
24.75%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.49
-2.23
-47.25%
MRKR
Marker Therapeutics
1.41
0.36
34.29%
RNAZ
TransCode Therapeutics
8.96
-1.90
-17.50%
Kazia Therapeutics Corporate Events
Kazia Therapeutics Announces Board Changes and AGM Outcomes as It Highlights Oncology Pipeline
Apr 1, 2026
On March 26, 2026, Kazia Therapeutics Limited, a Sydney-based clinical-stage oncology company focused on high-need CNS cancers and aggressive solid tumors, announced that Chairman Bryce Carmine had notified the board of his intention to retire. Hi...
Kazia Therapeutics Taps Leerink for New ATM Facility as Cash Bolstered by Late-2025 PIPE
Mar 30, 2026
Kazia Therapeutics Limited, an Australian oncology-focused RD company developing assets such as paxalisib and EVT801 and listed on Nasdaq via ADSs, reported a net loss of $12.6 million for the half year to 31 December 2025, with operating cash out...
Kazia Therapeutics Posts Wider Half-Year Loss but Bolsters Cash, Pipeline and Nasdaq Compliance
Mar 19, 2026
Kazia Therapeutics reported unaudited half-year results for the six months to December 31, 2025, on March 16, 2026, showing a post-tax loss of $12.55 million, widening from $10.45 million a year earlier. Despite higher operating losses and cash ou...
Kazia Therapeutics Posts Early Efficacy Signals for Paxalisib Combo in Metastatic Triple-Negative Breast Cancer
Jan 27, 2026
On January 27, 2026, Kazia Therapeutics reported encouraging early clinical signals from an ongoing Phase 1b trial of paxalisib in combination with pembrolizumab and chemotherapy in late-stage metastatic triple-negative breast cancer, initiated in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.